doxecitine; doxribtimine · Ucb Inc · NDA 219792
Kygevvi
Earliest generic entry, as listed
19 Aug 2040
Blocked by patent: US 11649259.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11649259 | drug product, use U-4358 · sets the listed date | 19 Aug 2040 |
| US 10471087 | use U-4358 | 7 Aug 2036 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 3 Nov 2030 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219792 · 001 · RLD | for solution, oral | 2GM/PACKET;2GM/PACKET | 19 Aug 2040 |